Literature DB >> 15492245

Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma.

Yutaka Midorikawa1, Shuichi Tsutsumi, Kunihiro Nishimura, Naoko Kamimura, Makoto Kano, Hirohiko Sakamoto, Masatoshi Makuuchi, Hiroyuki Aburatani.   

Abstract

To identify the chromosomal aberrations associated with the progression of liver cancer, we applied expression imbalance map analysis to gene expression data from 31 hepatocellular carcinomas and 19 noncancerous tissues. Expression imbalance map analysis, which detects mRNA expression imbalance correlated with chromosomal regions, showed that expression gains of 1q21-23 (74%), 8q13-21 (48%), 12q23-24 (41%), 17q12-21(48%), 17q25 (25%), and 20q11 (22%) and losses of 4q13 (48%), 8p12-21 (32%), 13q14 (32%), and 17p13 (29%) were significantly associated with hepatocellular carcinoma. Most regions with altered expression identified by expression imbalance map were also identified in previous reports using comparative genomic hybridization. We demonstrated chromosomal copy number gain in 1q21-23 and loss in 17p13 by genomic quantitative PCR, suggesting that gene expression profiles reflect chromosomal alterations. Furthermore, expression imbalance map analysis revealed that more poorly differentiated hepatocellular carcinoma contain more chromosomal alterations, which are accumulated in a stepwise manner in the course of hepatocellular carcinoma progression: expression imbalance of 1q, 8p, 8q, and 17p occur as early events in hepatocarcinogenesis, and 12q, 17q25 and 20q occur as later events. In particular, expression gain of 17q12-21 and loss of 4q were seen to accumulate constantly through the dedifferentiation process. Our data suggest that gene expression profiles are subject to chromosomal bias and that expression imbalance map can correlate gene expression to gene loci with high resolution and sensitivity.

Entities:  

Mesh:

Year:  2004        PMID: 15492245     DOI: 10.1158/0008-5472.CAN-04-1275

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 2.  Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma.

Authors:  Leilei Chen; Tim Hon Man Chan; Xin-yuan Guan
Journal:  Acta Pharmacol Sin       Date:  2010-08-02       Impact factor: 6.150

3.  A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma.

Authors:  Paul C Schröder; Víctor Segura; José Ignacio Riezu; Bruno Sangro; José M Mato; Jesús Prieto; Enrique Santamaría; Fernando J Corrales
Journal:  Funct Integr Genomics       Date:  2011-05-12       Impact factor: 3.410

4.  Discovery of a new biomarker for gastroenterological cancers.

Authors:  Hiroyuki Aburatani
Journal:  J Gastroenterol       Date:  2005-03       Impact factor: 7.527

5.  An improved method for detecting and delineating genomic regions with altered gene expression in cancer.

Authors:  Björn Nilsson; Mikael Johansson; Anders Heyden; Sven Nelander; Thoas Fioretos
Journal:  Genome Biol       Date:  2008-01-21       Impact factor: 13.583

Review 6.  Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges.

Authors:  Yutaka Midorikawa; Masatoshi Makuuchi; Wei Tang; Hiroyuki Aburatani
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 7.  Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Authors:  Hui-Zi Chen; Shih-Yin Tsai; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 8.  Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Wei-Cheng Liu; Quan-Yan Liu
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

9.  Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.

Authors:  Daniel Benten; Gunhild Keller; Alexander Quaas; Jorg Schrader; Artur Gontarewicz; Stefan Balabanov; Melanie Braig; Henning Wege; Jurgen Moll; Ansgar W Lohse; Tim H Brummendorf
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

10.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Authors:  Yujin Hoshida; Sebastian M B Nijman; Masahiro Kobayashi; Jennifer A Chan; Jean-Philippe Brunet; Derek Y Chiang; Augusto Villanueva; Philippa Newell; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Stacey Gabriel; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.